Search results for:
dihydroergotamine
dihydroergotamine
| Drug Name |
Form |
Strength |
Formulary Unrestricted |
Formulary Restricted |
Non-Formulary |
Interchange |
| Brekiya |
INJECTION, SUBCUTANEOUS |
1 mg/mL |
|
|
|
|
| D.H.E. 45 |
SOLUTION, INJECTABLE |
1 mg/mL |
|
|
|
|
| Migranal, DHE Nasal, Atzumi |
SPRAY, NASAL |
4 mg/mL, 5.2 mg |
|
|
|
|
Last updated: Aug. 14, 2026
If nasal spray ordered, contact prescriber to discuss alternative formulary agents (DHE injection or ergotamine SL tab).
Brekiya (DHE autoinjector): Non-Formulary. Inpatients may use home supply or contact prescriber to discuss alternative formulary agents.
Reviewed: January 2017 (Pediatrics), January 2017, January 2026 (Brekiya), July 2026 (Atzumi)
Dihydroergotamine Mesylate (BREKIYA) Specialty Drug Summary.pdf
Dihydroergotamine Nasal Spray (ATZUMI) Spotlight.pdf